companydata.dkResistance Oncology ApS: Financial statements 2017
CVR: 36945125
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 51,356 and a net result of DKK 1,147,497. Equity amounted to DKK -12,154.
- Gross Profit
- 51,356 kr.
- Profit/Loss
- 1,147,497 kr.
- Equity
- -12,154 kr.
- Total Assets
- 51,884 kr.
- Employees
- 0
Find more companies like Resistance Oncology ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2017
Resistance Oncology ApS has published its interim report for the period July 1, 2015 – December 31, 2016.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by TIMPCO NB ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees. In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity amounted to DKK 325,631.